 |
|
|
|
|
|
Name: |
|
Donald P. Becker MD |
|
|
|
|
Title: |
|
Co-director, Brain Tumor Program |
|
|
|
|
|
|
Facility: |
|
UCLA Medical Center |
|
|
|
|
|
|
Location: |
|
Dept. Of Neurosurgery
10833 LeConte
Los Angeles, CA USA |
|
|
|
|
Phone: |
|
310-794-1222 |
|
|
|
|
|
|
Fax: |
|
|
|
|
|
|
Email: |
|
Click here to send an email |
|
|
|
|
|
|
Website: |
|
neurosurgery.ucla.edu/ |
|
|
|
|
|
|
|
Name: |
|
Marvin Bergsneider MD |
|
|
|
|
Title: |
|
Director, Intra-op MRI Program and Co-director Neuroendoscopy Program |
|
|
|
|
|
|
Facility: |
|
UCLA Medical Center |
|
|
|
|
|
|
Location: |
|
Dept. Of Neurosurgery
10833 LeConte
Los Angeles, CA USA |
|
|
|
|
Phone: |
|
310-206-4100 |
|
|
|
|
|
|
Fax: |
|
|
|
|
|
|
Email: |
|
Click here to send an email |
|
|
|
|
|
|
Website: |
|
neurosurgery.ucla.edu/ |
|
|
|
|
|
|
|
Name: |
|
Antonio DeSalles MD, PhD |
|
|
|
|
Title: |
|
Co-director Radiosurgery Program and Head of Stereotactic Surgery |
|
|
|
|
|
|
Facility: |
|
UCLA Medical Center |
|
|
|
|
|
|
Location: |
|
Dept Of Radiation Oncology
10833 LeConte
Los Angeles, CA USA |
|
|
|
|
Phone: |
|
310-794-1221 |
|
|
|
|
|
|
Fax: |
|
|
|
|
|
|
Email: |
|
Click here to send an email |
|
|
|
|
|
|
Website: |
|
neurosurgery.ucla.edu/ |
|
|
|
|
|
|
|
Name: |
|
Linda M. Liau MD, PhD |
|
|
|
|
Title: |
|
Co-director, Brain Tumor Program |
|
|
|
|
|
|
Facility: |
|
UCLA Medical Center |
|
|
|
|
|
|
Location: |
|
David Geffen School of Medicine at UCLA
10833 Le Conte Avenue, CHS 74-145
Los Angeles, CA USA |
|
|
|
|
Phone: |
|
310-267-2621 |
|
|
|
|
|
|
Fax: |
|
310-825-7245 |
|
|
|
|
Email: |
|
Click here to send an email |
|
|
|
|
|
|
Website: |
|
neurosurgery.ucla.edu/ |
|
|
|
|
|
|
|
Name: |
|
Michael Selch MD |
|
|
|
|
Title: |
|
Professor, Radiation Oncology |
|
|
|
|
|
|
Facility: |
|
UCLA Medical Center |
|
|
|
|
|
|
Location: |
|
Dept Of Radiation Oncology
10833 LeConte
Los Angeles, CA USA |
|
|
|
|
Phone: |
|
310-825-4966 |
|
|
|
|
|
|
Fax: |
|
|
|
|
|
|
Email: |
|
Click here to send an email |
|
|
|
|
|
|
Website: |
|
www.radonc.ucla.edu/ |
|
|
There are 17 listings:
|
|
|
|
|
|
Treatment
|
|
Location |
|
Last Updated |
|
|
|
Details |
|
Phase I Dose Escalation Study of Autologous Antigen-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas (e.g. Glioblastoma Multiforme, Anaplastic Astrocytoma) |
|
Los Angeles, CA
Los Angeles, CA |
|
01/24/2010 |
|
|
|
|
|
Details |
|
Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) |
|
Los Angeles, CA |
|
01/24/2010 |
|
|
|
Details |
|
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients |
|
Los Angeles, CA |
|
01/24/2010 |
|
|
|
|
|
Details |
|
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA |
|
12/30/2009 |
|
|
|
Details |
|
Phase I Trial of Aflibercept (VEGF Trap)with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Gliomas |
|
Los Angeles, CA |
|
10/27/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Los Angeles, CA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients |
|
Los Angeles, CA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
NABTC 04-02: Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
|
|
Los Angeles, CA |
|
10/03/2007 |
|
|
|
Details |
|
Phase I/II Study of ZD6474 (ZactimaTM) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma |
|
Los Angeles, CA |
|
08/19/2007 |
|
|
|
|
|
Details |
|
A Pilot Multicenter Phase I/II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme |
|
Los Angeles, CA |
|
08/19/2007 |
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Los Angeles, CA |
|
08/04/2007 |
|
|
|
|
|
Details |
|
PEG-Interferon alfa-2b With or Without Thalidomide in Treating Patients With Recurrent High-Grade Gliomas
|
|
Los Angeles, CA |
|
05/04/2006 |
|
|
|
Details |
|
A Randomized Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron) Alone or in Combination with Thalidomide in Adults with Recurrent High-Grade Gliomas |
|
Los Angeles, CA |
|
11/27/2005 |
|
|
|
|
|
Details |
|
Phase I Study of Tipifarnib and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA |
|
11/06/2005 |
|
|
|
|
|
